A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Study sponsor: MacroGenics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-04Actual
Enrollment · participants192Actual
Source updated2026-02-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.